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Abstract
Background: The development of new anti-migraine treatments is limited by the difficulty inassessing migraine
pain in laboratory animals. Depression of activity is one of the few diagnostic criteria formigraine that can be
mimicked in rats. The goal of the present study was to test the hypothesis thatdepression of home cage wheel
running is a reliable and clinically relevant method to assess migraine painin rats.
Methods: Adult female rats were implanted with a cannula to inject allyl isothiocyanate (AITC) onto the dura to
induce migraine pain, as has been shown before. Rats recovered from implantation surgery for 8 days in cages
containing a running wheel. Home cage wheel running was recorded 23 h a day. AITC and the migraine
medication sumatriptan were administered in the hour prior to onset of the dark phase.
Results: Administration of AITC caused a concentration-dependent decrease in wheel running that lasted 3 h. The
duration and magnitude of AITC-induced depression of wheel running was consistent following three repeated
injections spaced 48 h apart. Administration of sumatriptan attenuated AITC-induced depressionof wheel running
when a large dose (1 mg/kg) was administered immediately following AITC administration. Wheel running patterns
did not change when sumatriptan was given to naïve rats.
Conclusions: These data indicate that home cage wheel running is a sensitive, reliable, and clinically relevant
method to assess migraine pain in the rat.
Keywords: TRPA1, Headache, Voluntary activity, Nociception, Pain-depressed behavior
Background
Migraine is characterized by severe pain and heightened
sensitivity to sensory stimuli that results in depression of
normal daily activities. Migraine is difficult to study in la-
boratory animals because pain occurs in the absence of
tissue injury and because of the limitations of existing be-
havioral assays [27]. Most preclinical studies of migraine
assess periorbital and/or hindpaw allodynia as the
dependent measure for migraine pain. Although migraine
causes allodynia in a subset of migraineurs, allodynia is
not a diagnostic criterion [12]. Moreover, allodynia is con-
sidered a marker of migraine progression [5, 16], rarely
assessed clinically [19], and may outlast the headache and
be present during interictal periods [1]. Thus, the develop-
ment of better ways to assess migraine pain in laboratory
animals would significantly advance migraine research.
In contrast to allodynia, the reduction in routine
physical activity caused by migraine is a diagnostic
criterion that is easy to replicate in laboratory animals.
A number of studies have used depression of activity
(e.g., locomotor activity, feeding, rearing) to assess pain
resulting from headache in humans [18] and rodents [7, 9,
17, 20, 28]. The problem with these studies is that assess-
ment was limited to 60 min or less making it impossible
to quantify the full duration and magnitude of the
migraine. In humans, the time course for the headache
phase of migraine can last from 4 to 72 h.
We have recently shown that home cage wheel running
is a sensitive and objective method to assess the magnitude
and duration of chronic inflammatory pain [14]. Home
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cage wheel running is an especially good model of human
activity because it is a voluntary behavior that shows clear
diurnal rhythms that can be continuously and objectively
quantified in the rat in a stress-free environment [14]. The
primary goal of the present study was to test the hypoth-
esis that home cage wheel running is a sensitive, reliable,
and clinically relevant method to assess the duration and
magnitude of migraine pain in laboratory rats.
Although a number of different animal models of
migraine have been developed (e.g., dural inflammatory
soup, systemic nitroglycerin), we used microinjection of the
TRPA1 agonist allyl isothiocyanate (AITC) onto the dura to
generate migraine pain. Similar to inflammatory soup,
AITC is a simple and direct method to activate the dural af-
ferents responsible for headache pain. Moreover, activation
of TRPA1 degranulates mast cells to release histamine and
serotonin [10] – all of which are key components of mi-
graine pathophysiology [2]. TRPA1 receptors have also
been shown to contribute to migraine in both humans and
rodents [9, 21]. The clinical relevance of home cage wheel
running as a method to assess migraine will be evaluated
by determining whether AITC produces a concentration-
dependent depression of wheel running that can be re-
versed by the migraine treatment sumatriptan. Reliability
will be assessed by measuring the consistency of AITC to
depress home cage wheel running following injections on
different days. All of the experiments were conducted in
female rats to be consistent with the much higher rates of
migraine in women than men [25, 26].
Methods
Subjects
Data were collected from 64 adult female Sprague-Dawley
rats bred at Washington State University Vancouver
(Vancouver, WA, USA). All rats were 50–70 days old at
the start of the study and randomly assigned to treatment
groups. A within-subjects design was used when possible
to reduce the number of animals needed. All procedures
were approved by the Washington State University
Animal Care and Use Committee and conducted in
accordance with the International Association for the Study
of Pain’s Policies on the Use of Animals in Research.
Surgery
Prior to surgery, rats were housed in pairs in a 22–24 °C
colony room on a 12/12-hour light/dark cycle (lights off
at 1800 h). Animals were anesthetized with pentobarbital
(50 mg/kg, i.p.) and implanted with a guide cannula (18
gauge; 4 mm long) aimed above the dura mater (AP:
+1.0 mm; ML: +1.0 mm; DV: 0.8 mm). Loctite® super glue
(Henkel AG & Company, KGaA, Düsseldorf, Germany)
was used to form a tight seal around the guide cannula and
skull, and then dental cement was used to anchor the guide
cannula to two screws in the skull. Rats were
maintained under a heat lamp until awake. Following
surgery, each rat was housed individually in an extra
tall cage (36 × 24 × 40 cm) with a running wheel.
The rat was allowed to recover for 8 days following
surgery in a sound-attenuating booth (2.1 × 2.2 m;
Industrial Acoustics Company, Inc., Bronx, NY, USA).
Food and water were available ad libitum.
Running wheel
A Kaytee Run-Around Giant Exercise Wheel (Kaytee
Products, Inc., Chilton, WI, USA) with a diameter of
27.9 cm was suspended from the top of the rat’s home cage.
The floor of the cage was covered with cellulose bedding
(BioFresh™, Ferndale, WA, USA). A thin aluminum plate
(0.8 mm × 5.08 cm × 3.81 cm; K&S Precision Metals, Chi-
cago, IL, USA) was attached to one spoke of the running
wheel to interrupt a photobeam projecting across the cage
with each rotation. The beam was set 18 cm above the floor
of the cage so that only the rotation of the wheel, not the
normal activity of the rat, would interrupt the beam. The
number of wheel revolutions were summed over 5 min bins
for 23 h each day using Multi-Varimex software (Columbus
Instruments, Columbus, OH, USA) beginning at 1700 h.
The dark phase of the light cycle when rats are most active
began at 1800 h. A full description of the running wheel
with video is available in our previous publication [14].
Drugs
Allyl isothiocyanate (AITC; Sigma-Aldrich, Inc., St. Louis,
MO, USA) was mixed in mineral oil at concentrations of
1 and 10% and injected into the periosteal space in a
volume of 10 μL. Sumatriptan succinate (Sigma-Aldrich,
Inc., St. Louis, MO, USA) was dissolved in saline (Hospira
Inc, Lake Forest, IL, USA) and injected subcutaneously at
doses of 0.1 and 1.0 mg/kg in a volume of 1 mL/kg. All
drugs were made fresh on the day it was injected.
Baseline acquisition
Rats were allowed unrestricted access to the wheel for
23 h/day for 8 days following surgery and prior to induc-
tion of migraine pain. The number of wheel revolutions
that occurred during the 23 h prior to the first dural in-
jection was used as the baseline activity level. Rats that
ran less than 400 revolutions on the baseline day (n = 7
out of 71) were not included in further testing [14].
Experiment 1: AITC concentration-response
If wheel running is a clinically relevant measure of
AITC-induced migraine pain, then the duration and
magnitude of depressed wheel running should depend
on the intensity of the headache. This hypothesis was
tested by measuring depression of wheel running to dif-
ferent concentrations of AITC. Following baseline test-
ing on Day 8, the rat was injected with 10 μL of 1%
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AITC, 10% AITC, saline, or mineral oil onto the dura
mater using an injection cannula inserted into the guide
cannula. All injections were complete by 1650 h. The rats
were returned to their home cage and wheel running
activity recorded for the next 23 h beginning at 1700 h.
This procedure was repeated every other day with the
drugs administered in a counterbalanced manner,
although no rat was treated in more than three conditions.
Rats were euthanized 48 h after the last injection.
Experiment 2: Repeated 10% AITC injections
If depression of wheel running is a reliable measure of
migraine pain, then the magnitude and duration of
AITC-induced depression of wheel running should be
consistent with repeated administration. This hypothesis
was tested by measuring wheel running following injec-
tion of 10% AITC onto the dura every other day until
the rat had received three injections. Surgical implant-
ation of the cannula, baseline testing, and timing of the
AITC injection was identical to Experiment 1.
Experiment 3: Sumatriptan efficacy against AITC-induced pain
If depression of wheel running is a clinically relevant
measure of migraine pain, then the anti-migraine medi-
cation sumatriptan should attenuate AITC-induced
depression of wheel running. This hypothesis was tested
by injecting sumatriptan (0.1 mg/kg and 1 mg/kg, s.c.)
or saline either 1 or 90 min post-AITC injection. Human
data demonstrates that sumatriptan is only effective if
administered soon after migraine onset [8]. In order to
administer sumatriptan 90 min after AITC administra-
tion, animals were removed from their home cages at
1500 h, injected with AITC, and returned to their home
cage. Rats were removed again 90 min later, injected
with sumatriptan (1 mg/kg, s.c.) or saline, and returned
to their home cage at approximately 1650 h. Wheel
running was measured for 23 h beginning at 1700 h. A
within-subjects, counterbalanced design was used so
that each rat was tested with AITC three times.
Saline was administered on one occasion and suma-
triptan on the other two. Some rats were tested with
different doses of sumatriptan while other rats were
tested at different times (1 or 90 min). Two days sep-
arated each dural injection.
Experiment 4: Sumatriptan effects on wheel running
In the absence of migraine pain, sumatriptan should
have no effect on wheel running. This hypothesis was
tested by injecting sumatriptan into naïve rats following
8 days of habituation to wheel running. These rats had
no surgery and were not treated with AITC. Rats were
removed from their home cages and injected with suma-
triptan (1 mg/kg, s.c.) or saline and returned to their
home cages at approximately 1650 h. Wheel running
was measured for 23 h beginning at 1700 h. A within-
subjects, counterbalanced design was used so that each
rat received both saline and sumatriptan injections. Two
days separated these injections.
Data analysis
Baseline activity was defined as the total number of
wheel revolutions during the 23 h preceding the first
injection. An average hourly nighttime running rate was
used as the baseline for hour-by-hour analysis. Given in-
dividual differences in wheel running, subsequent wheel
running data are presented as a percent change from
each rat’s baseline value. All data are expressed as mean ±
SEM. Nearly all running occurs during the dark phase of
the light cycle [14], so only data collected during the dark
phase and the one hour preceding the dark phase were
analyzed. Percentage of baseline running was averaged
over the 3-hour period following injection of AITC in
order to compare the magnitude of migraine-pain induced
depression of wheel running. Data were analyzed with an
independent samples t-test or one-way ANOVA. Because
animals whose guide cannulas were defective (n = 6) and
whose wheels malfunctioned (n = 6) were not available for
all of the within-subjects conditions, groups were treated
as independent samples. Statistical significance was de-
fined as a probability of < 0.05.
Results
Experiment 1: AITC concentration-response
Microinjection of AITC onto the dura caused a
concentration-dependent reduction in wheel running.
The highest concentration of AITC (10%) caused a pro-
nounced depression of wheel running that lasted for 3 h
(Fig. 1a). Administration of a lower concentration of
AITC caused a more modest and shorter lasting depres-
sion of wheel running (Fig. 1a). Analysis of the magni-
tude of AITC-induced depression of wheel running
during this 3-hour period (Fig. 1b) revealed a significant
difference in wheel running between AITC conditions
(F(3,173) = 7.459, p < 0.001). Post-hoc analysis revealed
that wheel running was significantly lower following
administration of 10% AITC compared to saline-, mineral
oil-, or 1% AITC-treated rats (Tukey test: Sal vs. 10%
AITC, p < 0.001; Mineral oil vs. 10% AITC, p = 0.016; 1%
vs. 10% AITC, p = 0.04). The depression in wheel running
following administration of 1% AITC was not significantly
different than saline- (Tukey test, p = 0.153) or mineral
oil-treated (Tukey test, p = 0.710) controls.
Experiment 2: Repeated 10% AITC injections
Rats were given three dural injections of 10% AITC to test
the reliability of repeated injections to depress wheel
running. Administration of 10% AITC caused a consistent
depression of wheel running that lasted approximately 3 h
Kandasamy et al. The Journal of Headache and Pain  (2017) 18:5 Page 3 of 8
following each injection (Fig. 2a). The magnitude of the de-
pression seemed to increase with each subsequent injection,
especially during the second hour, but, a one-way ANOVA
on total wheel running during the 3 h following AITC
administration revealed no significant differences between
the three injections (F(2,56) = 1.716, p = .189; Fig. 2b).
Experiment 3: Sumatriptan efficacy against AITC-induced
pain
Administration of the anti-migraine medication suma-
triptan immediately after injection of AITC attenuated
the depression of wheel running. Reversal of AITC-
induced depression of wheel running was first evident
2 h after sumatriptan administration and only following
administration of the highest dose (1.0 vs. 0.1 mg/kg)
(Fig. 3a). There was a significant difference in wheel
running during the first three hours following AITC
administration (Fig. 3b) in rats injected with 1 mg/kg of
sumatriptan compared to rats treated with saline or a
low dose of sumatriptan (0.1 mg/kg) (F(2,71) = 4.041,
p = .022).
A separate group of rats was injected with sumatriptan
(1 mg/kg) or saline 90 min after AITC administration to
determine whether sumatriptan could reverse migraine
pain once it had been established. Running patterns are
nearly identical between sumatriptan- and saline-treated
rats when injected 90 min after AITC (Fig. 4). Compari-
son of total wheel running in these two groups during
the 3 h following sumatriptan administration revealed
no differences between groups (t(43) = 0.002, p = .969).
Experiment 4: Sumatriptan effects on wheel running
Naïve rats were injected with either sumatriptan (1 mg/kg)
or saline to determine the effects of sumatriptan alone on
wheel running. Sumatriptan had no consistent effect on
wheel running in naïve animals (Fig. 5). Comparison
of these two groups during the first 3 h after
Fig. 1 Dural injection of AITC depresses home cage wheel running
in a concentration-dependent manner. a Administration of 10% AITC
depressed wheel running for 3 h. The magnitude and duration of
AITC-induced depression of wheel running was greatly reduced when
the concentration was reduced to 1%. b Total percent of wheel
revolutions during the 3 h following administration of 10% AITC (n= 17)
was significantly lower compared to animals receiving 1% AITC (n
= 20), mineral oil (n = 7), or saline (n = 14). *indicates p < 0.001 vs.
saline, p = 0.016 vs. mineral oil, p = 0.04 vs. 1% AITC
Fig. 2 Consistent depression of wheel running following repeated
injections of 10% AITC onto the dura. a Administration of 10% AITC
depressed wheel running for approximately 3 h on all three trials.
The magnitude of depressed wheel running was greatest following
the third AITC injection, especially during the second hour, although
this difference did not reach statistical significance when total wheel
revolutions during the 3 h following AITC administration were
analyzed (see Fig b). n = 6–7/condition
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sumatriptan administration revealed no significant dif-
ference (t(94) = .860, p = .392).
Discussion
The present data indicate that depression of home cage
wheel running is a reliable and clinically relevant
method to assess migraine pain in laboratory rats.
AITC-induced activation of dural afferents produced a
concentration-dependent reduction in wheel running
that persisted for at least 3 h. Repeated injections of 10%
AITC onto the dura caused a consistent reduction in
wheel running following each injection. Finally, adminis-
tration of the anti-migraine medication sumatriptan pro-
duced a dose-dependent reversal of AITC-induced
depression of wheel running when administered imme-
diately after the AITC injection, but did not affect wheel
running in pain-free animals.
Our finding that dural administration of AITC pro-
duces a 3 h reduction in wheel running confirms
Fig. 3 Administration of sumatriptan reverses AITC-induced depression
of wheel running. a Administration of the high (1 mg/kg), but not the
low dose (0.1 mg/kg) of sumatriptan immediately after administration
of AITC shortened the duration of AITC-induced depression of wheel
running. b Recovery of wheel running in the 3 h following sumatriptan
(1 mg/kg; n = 11) administration was significantly greater following
administration of 1 mg/kg of sumatriptan compared to rats treated
with 0.1 mg/kg (n = 7) or saline (n = 7). *indicates p < 0.05 vs. saline
Fig. 5 Sumatriptan had no effect on wheel running in rats not treated
with AITC. a Wheel running was variable following administration of
sumatriptan (1 mg/kg) or saline (1 mL/kg) in the absence of headache.
Neither sumatriptan (n= 14) nor saline (n= 18) depressed wheel running.
b Wheel running was unaffected in the 3 h following sumatriptan
or saline
Fig. 4 Sumatriptan injected 90 min after induction of headache did
not reverse AITC-induced depression of wheel running. Sumatriptan
(1 mg/kg) or saline (1 mL/kg) was injected 90 min after dural injection
of 10% AITC. Administration of sumatriptan (n = 8) at this time point
had no effect on depressed wheel running compared to saline-treated
animals (n = 7)
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previous studies indicating that activation of TRPA1
receptors produces migraine-like pain. TRPA1 receptors
have been shown to contribute to migraine in both
human and rat. Activation of trigeminal TRPA1 recep-
tors causes meningeal vasodilation and calcitonin gene-
related peptide release in rodents [21] and periorbital
and hindpaw allodynia [9]. Case studies have reported
that inhalation of TRPA1 agonists can trigger headache
in people [3, 21].
Although the depression of wheel running following
AITC administration onto the dura lasted for 3 h, the
diagnostic criterion for migraine in humans requires a
duration of a minimum of 4 h [12]. It is unlikely that
AITC administration produces a syndrome that fully
replicates a human migraine. Dural administration of an
“inflammatory soup” has also been used to induce
migraine-like pain, but neither of these models truly
captures a human migraine. Given that migraine is a
complicated process that involves the brain, local blood
vessels, and trigeminal afferents [13], simple chemical
activation of dural afferents via AITC or inflammatory
soup is unlikely to engage all of these systems. However,
the three-hour depression of wheel running reported in
this manuscript and the widespread allodynia reported
by others [9] suggests that administration of AITC
mimics migraine-like pain.
Previous studies have shown that administration of
AITC to the dura produces allodynia that persists for up
to 5 h post-injection [9] - significantly longer than depres-
sion of wheel running. Given that allodynia may be
present during interictal phases [1], it is likely that asses-
sing allodynia as a measure of migraine in rodents may be
confounded by allodynia being present in either the post-
drome phase of a migraine attack or the interictal period.
Furthermore, given that dural AITC-induced hindpaw
allodynia persists for 5 h, it is unlikely that depression of
wheel running is caused by hindpaw allodynia.
We also show that repeated AITC administration did not
cause a significant increase in the magnitude or duration of
depression of wheel running. A trend towards greater de-
pression of wheel running was evident with repeated injec-
tions, particularly in the second hour post-AITC (Fig. 2a),
but this difference did not reach statistical significance. A
floor effect may have prevented the expression of more
intense pain. Sensitization of the trigeminovascular system
has been demonstrated using multiple dural infusions of in-
flammatory soup [20, 22] so a similar enhancement would
be expected with repeated AITC injections. These findings
suggest that it may be possible to induce chronic migraine
with repeated dural injections of AITC. Continuous home
cage wheel running would provide an objective and simple
method to detect potential spontaneous migraines,
especially if the incidence of chronic migraine arises in only
a subset of animals as is the case with humans.
Sumatriptan is a prototypical anti-migraine agent and
has been used to demonstrate the predictive validity of
migraine models. Our data showing that sumatriptan is
only effective in reversing AITC-induced depression of
wheel running when given at a sufficient dose (1 mg/kg)
and latency following induction of headache further vali-
dates home cage wheel running as a method to assess
migraine in rats. Sumatriptan had no efficacy when
administered 90 post-AITC injection (Fig. 4) as has been
reported in humans where the efficacy of triptans is
attenuated if patients wait to take the drug [8]. Further-
more, similar to the clinical situation [31], our data suggest
that sumatriptan relieves pain 2 h after its administration
(Fig. 3a). Although pre-treatment of sumatriptan may
prevent AITC-induced depression of wheel running as has
been reported previously with other behaviors [9, 20],
triptans are generally considered abortive anti-migraine
agents, and thus, are rarely taken before the onset of
migraine symptoms.
Depression of wheel running is also a clinically relevant
method to assess migraine pain in rats in that it mimics
the reduction in normal physical activity characteristic of
migraine in humans [12]. Migraine has been reported to
reduce activity for 57.3 million days per year for women
[26], and is often so severe as to require bed rest [4]. Our
data showing depression of home cage wheel running is
consistent with these clinical observations.
Assessment of home cage wheel running provides a
number of advantages over other tests to assess migraine
pain in animals. In contrast to pain-evoked methods to
assess migraine such as assessing periorbital and/or
hindpaw allodynia, which may induce stress by testing
the animal in a novel environment, home cage wheel
running reveals the effect of spontaneous migraine pain
in a stress-free environment. Moreover, data collection is
objective, independent of the researcher, and captures
both the magnitude and duration of migraine pain.
Given that home cage wheel running is also sensitive
to the disruptive side effects of analgesics [15], this test
allows existing and experimental treatments to be simul-
taneously evaluated for both anti-migraine efficacy and
side effect profile. This key advantage separates home
cage wheel running from traditional tests of migraine
pain in rats such as assessment of allodynia, which can
be blocked by drugs with either antinociceptive or seda-
tive effects. A key goal of drug treatment should be to
restore function as opposed to replacing one problem
(pain) with another (sedation).
Although depression of wheel running provides an
objective and clinically relevant measure of migraine
pain, exercise itself has been shown to reduce pain [11].
However, this type of exercise-induced antinociception
typically requires multiple weeks of daily wheel running
[24]. Our previous studies [14, 15] and those of others
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[30] show that 5–8 days of baseline wheel running has
no direct antinociceptive effect. These findings are
consistent with human behavior in that consistent
prolonged exercise can be used to maintain health,
whereas pain or illness will disrupt a person’s exercise
regimen.
The present data build a firm foundation for the use of
home cage wheel running to assess migraine pain in rats.
The obvious problem with preclinical migraine research
is that it does not mimic the spontaneous onset of
migraine. Both pharmacological [23] and genetic [6] ap-
proaches have attempted to overcome this disconnect
between preclinical models and the human situation. As
before, these procedures have been limited because of
the inability to continuously monitor migraine pain-
related decreases in behavior. Assessment of home cage
wheel running provides a simple method to detect such
seemingly random occurrences of migraine in a subset
of animals. The validity of home cage wheel running as
a preclinical method to assess migraine will be tested in
future studies by examining the effects of prophylactic
and other abortive anti-migraine therapies.
Female rats were used in the present study to enhance
the clinical relevance of the research given that migraine
is more common in women than men [25, 26]. Given
that the higher incidence of migraine in women has
been linked to female sex hormones [29], one would
predict that the magnitude and duration of migraine-
induced depression of wheel running would be greater
in female than male rats, and vary depending on the
phase of the estrous cycle. However, the occurrence of
sex differences may require the use of a more natural
migraine model (e.g., systemic nitric oxide donor) as
opposed to that induced by an irritant such as AITC or
inflammatory soup.
Conclusions
In sum, the results of the present study demonstrate that
home cage wheel running objectively captures headache-
induced depression of activity that closely resembles mi-
graine pain in patients. It is an easy-to-use test that allows
precise quantification of the magnitude and duration of
migraine pain. The use of home cage wheel running
should help unveil the pathophysiology underlying migrai-
neheadache and provide a clinically relevant method to as-
sess the anti-migraine efficacy of novel therapeutics.
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